MX2018012898A - Polimorfismo cristalino del activador del canal controlado por voltaje de potasio de subfamilia kqt subtipos 2-5 (kcnq2-5). - Google Patents

Polimorfismo cristalino del activador del canal controlado por voltaje de potasio de subfamilia kqt subtipos 2-5 (kcnq2-5).

Info

Publication number
MX2018012898A
MX2018012898A MX2018012898A MX2018012898A MX2018012898A MX 2018012898 A MX2018012898 A MX 2018012898A MX 2018012898 A MX2018012898 A MX 2018012898A MX 2018012898 A MX2018012898 A MX 2018012898A MX 2018012898 A MX2018012898 A MX 2018012898A
Authority
MX
Mexico
Prior art keywords
crystal
kcnq
polymorphism
crystal polymorphism
channel activator
Prior art date
Application number
MX2018012898A
Other languages
English (en)
Inventor
Kijima Hideomi
Yashiro Kentaro
Wakamatsu Daisuke
Saito Tetsuji
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2018012898A publication Critical patent/MX2018012898A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El polimorfismo cristalino puede estar presente en un compuesto cristalino. En el caso en donde exista polimorfismo cristalino, dependiendo de la forma cristalina, es diferente la solubilidad, la velocidad de disolución, o la estabilidad contra el calor, la luz, la humedad y semejantes. De acuerdo con esto, en la producción de medicamentos, es una tarea muy importante seleccionar una forma cristalina de una sustancia farmacéutica más adecuada para la enfermedad indicada y una forma de dosificación. La presente invención se refiere a una nueva forma cristalina (cristal A, cristal W, y cristal de un hidrato (cristal H)) del compuesto I que tiene una fuerte acción de abertura con respecto a los canales de KCNQ 2-5.
MX2018012898A 2016-04-22 2017-04-21 Polimorfismo cristalino del activador del canal controlado por voltaje de potasio de subfamilia kqt subtipos 2-5 (kcnq2-5). MX2018012898A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016086239 2016-04-22
PCT/JP2017/016109 WO2017183725A1 (ja) 2016-04-22 2017-04-21 Ｋｃｎｑ２～５チャネル活性化剤の結晶多形

Publications (1)

Publication Number Publication Date
MX2018012898A true MX2018012898A (es) 2019-01-30

Family

ID=60116201

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012898A MX2018012898A (es) 2016-04-22 2017-04-21 Polimorfismo cristalino del activador del canal controlado por voltaje de potasio de subfamilia kqt subtipos 2-5 (kcnq2-5).

Country Status (15)

Country Link
US (1) US20190135755A1 (es)
EP (1) EP3447047A1 (es)
JP (1) JP6265313B1 (es)
KR (1) KR20180135448A (es)
CN (1) CN109071441A (es)
AU (1) AU2017254257A1 (es)
BR (1) BR112018071654A2 (es)
CA (1) CA3021624A1 (es)
IL (1) IL262439A (es)
MX (1) MX2018012898A (es)
PH (1) PH12018502228A1 (es)
RU (1) RU2018136892A (es)
SG (1) SG11201809184VA (es)
WO (1) WO2017183725A1 (es)
ZA (1) ZA201807006B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
WO2013156154A1 (en) * 2012-04-18 2013-10-24 Grünenthal GmbH Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators
BR112015012418A2 (pt) * 2012-11-28 2017-07-11 Gruenenthal Gmbh carboxamidas específicas como moduladores de kcnq2/3
RU2712163C2 (ru) * 2014-10-24 2020-01-24 Оно Фармасьютикал Ко., Лтд. Активатор kcnq2-5 каналов

Also Published As

Publication number Publication date
CA3021624A1 (en) 2017-10-26
ZA201807006B (en) 2019-07-31
EP3447047A4 (en) 2019-02-27
IL262439A (en) 2018-12-31
CN109071441A (zh) 2018-12-21
PH12018502228A1 (en) 2019-07-08
JP6265313B1 (ja) 2018-01-24
SG11201809184VA (en) 2018-11-29
US20190135755A1 (en) 2019-05-09
AU2017254257A1 (en) 2018-11-15
EP3447047A1 (en) 2019-02-27
BR112018071654A2 (pt) 2019-02-19
WO2017183725A1 (ja) 2017-10-26
RU2018136892A (ru) 2020-05-22
JPWO2017183725A1 (ja) 2018-04-26
KR20180135448A (ko) 2018-12-20

Similar Documents

Publication Publication Date Title
MX2020007485A (es) Compuestos antiproliferativos y metodos de uso de los mismos.
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
MY196243A (en) Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2017013797A (es) Inhibidor de janus quinasa.
MX2016006564A (es) Compuestos dihidropirimidina y su aplicacion en productos farmaceuticos.
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
EA201690127A1 (ru) Состав на основе ингибиторов syk
GEP20197043B (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
GEP20186933B (en) Substituted dihydroisoquinoline compounds
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
WO2018125880A8 (en) Nrf2 activator
EA201692270A1 (ru) Производные нафтиридиндиона
WO2016100302A3 (en) Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
MX2015012386A (es) Inhibidores de la cinasa cdk9.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
PH12018502228A1 (en) Crystal polymorphism of kcnq 2-5 channel activator
EA201891240A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds
TH1601001978A (th) สูตรผสมของ (s)-3-(4-((4-(มอร์โพลิโนเมธิล)เบนซิล)ออกซิ)-1-ออกโซไอโซอินโดลิน-2-อิล)ไพเพอริดีน-2,6-ไดโอน
PL414926A1 (pl) Zastosowanie medyczne N-podstawionych pochodnych 3-amino-4-fenylo-5-oksopirazolinokarboksamidu do wytwarzania leku